Abstract
Although genome-wide association studies (GWAS) have identified the existence of numerous population-based cancer susceptibility loci, mechanistic insights remain limited, particularly for intergenic polymorphisms. Here, we show that polymorphism at a remote intergenic region on chromosome 11q13.3, recently identified as a susceptibility locus for renal cell carcinoma1, modulates the binding and function of hypoxia-inducible factor (HIF) at a previously unrecognized transcriptional enhancer of CCND1 (encoding cyclin D1) that is specific for renal cancers characterized by inactivation of the von Hippel–Lindau tumor suppressor (pVHL). The protective haplotype impairs binding of HIF-2, resulting in an allelic imbalance in cyclin D1 expression, thus affecting a link between hypoxia pathways and cell cycle control.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Purdue, M.P. et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat. Genet. 43, 60–65 (2011).
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917 (2010).
Gnarra, J.R. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7, 85–90 (1994).
Herman, J.G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91, 9700–9704 (1994).
Maxwell, P.H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Jaakkola, P. et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).
Ivan, M. et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).
Kaelin, W.G. Jr. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat. Rev. Cancer 8, 865–873 (2008).
Kondo, K., Kim, W.Y., Lechpammer, M. & Kaelin, W.G. Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1, E83 (2003).
Raval, R.R. et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25, 5675–5686 (2005).
Yan, Q., Bartz, S., Mao, M., Li, L. & Kaelin, W.G. Jr. The hypoxia-inducible factor 2α N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol. Cell. Biol. 27, 2092–2102 (2007).
Gordan, J.D. et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435–446 (2008).
Shen, C. et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Cancer Discov. 1, 222–235 (2011).
Morris, M.R. et al. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. Anticancer Res. 29, 4337–4343 (2009).
Dalgliesh, G.L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360–363 (2010).
Varela, I. et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469, 539–542 (2011).
Wu, X. et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum. Mol. Genet. 21, 456–462 (2012).
Cao, Q. et al. Chromosome 11q13.3 variant modifies renal cell cancer risk in a Chinese population. Mutagenesis published online (30 November 2011), doi:10.1093/mutage/ger085.
Schödel, J. et al. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117, e207–e217 (2011).
Giresi, P.G., Kim, J., McDaniell, R.M., Iyer, V.R. & Lieb, J.D. FAIRE (formaldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. Genome Res. 17, 877–885 (2007).
Heintzman, N.D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311–318 (2007).
Creyghton, M.P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 107, 21931–21936 (2010).
Rada-Iglesias, A. et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279–283 (2011).
Gumz, M.L. et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin. Cancer Res. 13, 4740–4749 (2007).
Kaelin, W.G. Jr. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115, 2262–2272 (2009).
Musgrove, E.A., Caldon, C.E., Barraclough, J., Stone, A. & Sutherland, R.L. Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558–572 (2011).
Zatyka, M. et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 62, 3803–3811 (2002).
Bindra, R.S., Vasselli, J.R., Stearman, R., Linehan, W.M. & Klausner, R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62, 3014–3019 (2002).
Baba, M. et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22, 2728–2738 (2003).
Wykoff, C.C. et al. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 90, 1235–1243 (2004).
Dekker, J., Rippe, K., Dekker, M. & Kleckner, N. Capturing chromosome conformation. Science 295, 1306–1311 (2002).
Hu, C.J., Sataur, A., Wang, L., Chen, H. & Simon, M.C. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell 18, 4528–4542 (2007).
Lau, K.W., Tian, Y.M., Raval, R.R., Ratcliffe, P.J. & Pugh, C.W. Target gene selectivity of hypoxia-inducible factor-α in renal cancer cells is conveyed by post-DNA-binding mechanisms. Br. J. Cancer 96, 1284–1292 (2007).
Mandriota, S.J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459–468 (2002).
Xia, X. et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc. Natl. Acad. Sci. USA 106, 4260–4265 (2009).
Krieg, A.J. et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 α enhances hypoxic gene expression and tumor growth. Mol. Cell. Biol. 30, 344–353 (2010).
Pescador, N. et al. Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem. J. 390, 189–197 (2005).
Mole, D.R. et al. Genome-wide association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284, 16767–16775 (2009).
Brown, J. et al. Subtelomeric chromosome rearrangements are detected using an innovative 12-color FISH assay (M-TEL). Nat. Med. 7, 497–501 (2001).
Brown, J.M. et al. Coregulated human globin genes are frequently in spatial proximity when active. J. Cell Biol. 172, 177–187 (2006).
Hagège, H. et al. Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protoc. 2, 1722–1733 (2007).
Ramachandrareddy, H. et al. BCL6 promoter interacts with far upstream sequences with greatly enhanced activating histone modifications in germinal center B cells. Proc. Natl. Acad. Sci. USA 107, 11930–11935 (2010).
Lo, H.S. et al. Allelic variation in gene expression is common in the human genome. Genome Res. 13, 1855–1862 (2003).
Acknowledgements
Samples of renal tumors were a gift from A.L. Harris through the Oxford Radcliffe Biobank, Oxford Biomedical Research Centre. HKC-8 cells were provided by L. Racusen (Johns Hopkins University), 786-O cells re-expressing pVHL were a gift from W.G. Kaelin Jr. (Harvard Medical School), RCC4 cells were a gift from C.H. Buys (University of Groningen), and all other RCC cells were from M. Lerman (National Institutes of Health). This work was funded by the Wellcome Trust (088182/Z/09/Z, 078333/Z/05/Z and WT091857MA to J.S.), the Higher Education Funding Council for England, the German Research Foundation (SC 132/2-1 to L.K.S.) and by Urology Cancer Research and Education (UCARE).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–7 (PDF 4423 kb)
Rights and permissions
About this article
Cite this article
Schödel, J., Bardella, C., Sciesielski, L. et al. Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat Genet 44, 420–425 (2012). https://doi.org/10.1038/ng.2204
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2204
This article is cited by
-
GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression
Journal of Experimental & Clinical Cancer Research (2023)
-
Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors
Signal Transduction and Targeted Therapy (2023)
-
UBE3B promotes breast cancer progression by antagonizing HIF-2α degradation
Oncogene (2023)
-
Microbiota-assisted iron uptake promotes immune tolerance in the intestine
Nature Communications (2023)
-
Prediction of mammalian tissue-specific CLOCK–BMAL1 binding to E-box DNA motifs
Scientific Reports (2023)